Clear 618 Results Filter Filter Results Type: Press Release National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery Type: Press Release Impella SmartAssist Platform Launches at SCAI Designed to Further Improve Patient Outcomes Type: Press Release FDA Approves Impella 50 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy Type: Press Release FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial Type: Press Release Abiomed Announced Q4 FY 2019 Revenue of $207 Million and 316% Operating Margin Type: Press Release Clinical Data Highlights Advantages of Protected PCI to Enable Complete Revascularization and Improved Patient Quality of Life Type: Press Release Abiomed Fourth Quarter Fiscal 2019 Earnings and Conference Call Notification Type: Press Release Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval Type: Press Release Impella RP Post-Approval Study Data Presented at ACC 2019 Type: Press Release Benefits of Heart Recovery with Impella Showcased at ACC 2019 … 29 30 31 32 …
